Company Overview and News

Stocks ride out volatility to end modestly higher

Mumbai: Markets ended with mild gains today after yet another choppy session as investors kept their faith in consumption stocks amid an encouraging start to the earnings season.
Upvote Downvote

Closing Bell: Sensex ends flat, Nifty below 10,600; pharma gains

5h moneycontrol
3:30 pm Market at Close: The market began the week on a good note, but have ended flat now. The Nifty managed to breach 10,600-mark.
Upvote Downvote

Sensex, Nifty turn choppy on mixed global cues

Mumbai: Domestic equities opened on a choppy note today tracking mixed cues from other Asian markets, ahead of F&O expiry later this week. The benchmark BSE Sensex, which had lost 11.71 points in the previous session on Friday, rose 78.11 points, only to turn negative within minutes of session opening. The 30-share index was trading 15.24 points, or 0.04 per cent, lower at 34,400.34, with metals and banking stocks leading the losses.
Upvote Downvote

Market Update: Oil gas stocks gain led by HPCL, BPCL; HDFC Bank most active, TCS hits new record high

9h moneycontrol
The Indian equity market was trading on a flat to negative note on Monday morning with the Nifty shedding 5 points was trading at 10,558 while the Sensex was down 50 points or 0.15 percent.
Upvote Downvote

Firms in BSE auto index likely to post robust Q4 results

16h livemint
Mumbai: Automobile companies are set to report strong revenue and operating profit growth in the March quarter because of a revival in rural demand and a low-base effect following the negative impact of demonetisation that lasted well into the fourth quarter of the previous financial year.
Upvote Downvote

Hero MotoCorp Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-04-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Upvote Downvote

Sensex falls over 50 points on negative global cues, weak rupee

Mumbai: The benchmark BSE Sensex declined by about 80 points in early session today, in tandem with weak global cues amid rupee’s plunge below the 66 mark. Besides, the release of the minutes of last Monetary Policy Committee (MPC) meeting on April 4-5, indicating the Reserve Bank of India may shift to a hawkish monetary stance in June, weighed on investor sentiment.
Upvote Downvote

SaaS startup Fyle gets funding from Pravega and Beenext

2018-04-19 livemint
Bengaluru: Bengaluru-based Fyle, which provides expense management software for enterprises, has raised an undisclosed amount in funding from existing investors Pravega Ventures and Beenext, a Singapore-based venture capital firm.
Upvote Downvote

Fortis jumps 3% as Hero-Burman combine raises offer price

2018-04-19 thehindubusinessline
Fortis, which runs about 30 hospitals across India, has become the target of a takeover battle, with Malaysia's IHH Healthcare Bhd, local rival Manipal Health Enterprises Pvt Ltd and China's Fosun International Ltd vying for the cash-strapped company.
Upvote Downvote

Fortis Healthcare gets improved offer from Hero Enterprise, Burman Family

2018-04-19 livemint
Fortis Healthcare Ltd said on Thursday it had received an improved binding offer worth Rs1,500 crore from Hero Enterprise Investment Office and Burman Family Office. The proposal is higher than their last week’s offer of Rs1,250 crore.
Upvote Downvote

Hero MotoCorp Limited - Press Release

2018-04-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Upvote Downvote

Kedaara Capital may buy Munjals’ Sunbeam Auto for Rs650 crore

2018-04-17 livemint
Mumbai: Private equity fund Kedaara Capital Investment Managers Ltd is in final stages of discussions to acquire Rajasthan-based auto component maker Sunbeam Auto Ltd for $100 million (Rs650 crore), two people aware of the development said.
Upvote Downvote

Fortis Healthcare raises Rs150 crore debt to stave off bankruptcy

2018-04-16 livemint
Mumbai: Fortis Healthcare Ltd, which is weighing multiple takeover offers for its assets, has got a Rs150 crore bridge loan from RattanIndia Finance to keep the struggling hospital operator afloat till it finds a buyer, amid a credit squeeze.
Upvote Downvote

Last hour recovery lifts Nifty above 10,500, Sensex 113 pts; midcaps outperform

2018-04-16 moneycontrol
The recovery in the last hour of trade helped the market close higher for the eighth consecutive session on Monday despite sluggish global cues. Continued hopes of normal monsoon expected in the current year and favourable earnings season boosted sentiment.
Upvote Downvote

Market Update: Sensex, Nifty rebound as realty stocks outperform; HDFC Bank up 1%; Cipla top Nifty gainer

2018-04-16 moneycontrol
The Indian equity market was trading on a positive note on Monday afternoon with the Nifty adding 33 points and was trading above the 10,500 mark at 10,513 while the Sensex was up 95 points or 0.28 percent.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...